Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) EPS (Weighted Average and Diluted) (2021 - 2026)

Protara Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.31 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 6.9% to -$0.31 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.35 through Mar 2026, up 19.16% year-over-year, with the annual reading at -$1.34 for FY2025, 38.25% up from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.31 for Q1 2026, up from -$0.38 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.29 in Q1 2025 to a low of -$3.46 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.68 (2022), against an average of -$0.79.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 280.22% in 2022 and then soared 73.99% in 2023.
  • Protara Therapeutics' EPS (Weighted Average and Diluted) stood at -$3.46 in 2022, then skyrocketed by 73.99% to -$0.9 in 2023, then skyrocketed by 52.22% to -$0.43 in 2024, then grew by 11.63% to -$0.38 in 2025, then rose by 18.42% to -$0.31 in 2026.
  • Per Business Quant, the three most recent readings for TARA's EPS (Weighted Average and Diluted) are -$0.31 (Q1 2026), -$0.38 (Q4 2025), and -$0.31 (Q3 2025).